IQVIA Holdings Inc. $IQV Shares Sold by Kestra Advisory Services LLC

Kestra Advisory Services LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 51.1% in the first quarter, HoldingsChannel reports. The firm owned 3,373 shares of the medical research company’s stock after selling 3,531 shares during the quarter. Kestra Advisory Services LLC’s holdings in IQVIA were worth $575,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of IQVIA by 8.3% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,225,851 shares of the medical research company’s stock worth $209,057,000 after buying an additional 93,779 shares in the last quarter. Resona Asset Management Co. Ltd. lifted its stake in shares of IQVIA by 1.5% during the first quarter. Resona Asset Management Co. Ltd. now owns 53,692 shares of the medical research company’s stock valued at $9,112,000 after buying an additional 810 shares during the period. Nichols & Pratt Advisers LLP MA boosted its position in IQVIA by 6.4% during the first quarter. Nichols & Pratt Advisers LLP MA now owns 131,656 shares of the medical research company’s stock worth $22,453,000 after acquiring an additional 7,911 shares during the last quarter. Integrated Advisors Network LLC grew its stake in IQVIA by 6.1% in the 1st quarter. Integrated Advisors Network LLC now owns 7,613 shares of the medical research company’s stock worth $1,298,000 after acquiring an additional 441 shares during the period. Finally, Dumont & Blake Investment Advisors LLC acquired a new position in IQVIA in the 1st quarter valued at $1,175,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.1%

Shares of NYSE IQV opened at $208.22 on Monday. The stock has a market capitalization of $34.75 billion, a PE ratio of 25.80, a P/E/G ratio of 1.87 and a beta of 1.20. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a fifty day moving average of $188.23 and a 200-day moving average of $187.05. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the company posted $2.70 EPS. The business’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has initiated a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. Mizuho increased their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. HSBC reiterated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.